PMID- 35088160
OWN - NLM
STAT- MEDLINE
DCOM- 20220824
LR  - 20221028
IS  - 1432-198X (Electronic)
IS  - 0931-041X (Linking)
VI  - 37
IP  - 10
DP  - 2022 Oct
TI  - Considerations and possibilities for sodium-glucose cotransporter 2 inhibitors in 
      pediatric CKD.
PG  - 2267-2276
LID - 10.1007/s00467-022-05456-x [doi]
AB  - Sodium-glucose cotransporter 2 inhibitors (SGLT2is) were originally developed as 
      glucose-lowering agents. These medications function by inhibiting glucose and 
      sodium reabsorption in the S1 segment of the proximal tubule. Early clinical 
      trials in adults with type 2 diabetes mellitus (T2DM) suggested a significant 
      improvement in kidney and cardiovascular outcomes with SGLT2i therapy. Since 
      then, SGLT2is have become a mainstay treatment for adult patients with CKD. A 
      growing body of research has explored deploying these medications in new clinical 
      contexts and investigated the mechanisms underlying their physiologic effects. 
      However, patients under the age of 18 years have been largely excluded from all 
      major trials of SGLT2i. This review aims to summarize the available clinical 
      evidence, physiology, and mechanisms relating to SGLT2is to inform discussions 
      about their implementation in pediatrics.
CI  - (c) 2022. The Author(s), under exclusive licence to International Pediatric 
      Nephrology Association.
FAU - Kula, Alexander J
AU  - Kula AJ
AD  - Division of Pediatric Nephrology, Seattle Children's Hospital, University of 
      Washington, Seattle, WA, USA. alexkula@luriechildrens.org.
AD  - Division of Pediatric Nephrology, Ann & Robert H. Lurie Children's Hospital of 
      Chicago, 225 Chicago Ave., IL, Chicago, USA. alexkula@luriechildrens.org.
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20220127
PL  - Germany
TA  - Pediatr Nephrol
JT  - Pediatric nephrology (Berlin, Germany)
JID - 8708728
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 9NEZ333N27 (Sodium)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Glucose/therapeutic use
MH  - Humans
MH  - Hypoglycemic Agents
MH  - *Renal Insufficiency, Chronic/chemically induced/drug therapy
MH  - Sodium
MH  - *Sodium-Glucose Transporter 2 Inhibitors/pharmacology/therapeutic use
OTO - NOTNLM
OT  - Mechanisms
OT  - Pediatric CKD
OT  - SGLT2 inhibitor
EDAT- 2022/01/29 06:00
MHDA- 2022/08/25 06:00
CRDT- 2022/01/28 05:56
PHST- 2021/10/01 00:00 [received]
PHST- 2021/12/28 00:00 [accepted]
PHST- 2021/12/28 00:00 [revised]
PHST- 2022/01/29 06:00 [pubmed]
PHST- 2022/08/25 06:00 [medline]
PHST- 2022/01/28 05:56 [entrez]
AID - 10.1007/s00467-022-05456-x [pii]
AID - 10.1007/s00467-022-05456-x [doi]
PST - ppublish
SO  - Pediatr Nephrol. 2022 Oct;37(10):2267-2276. doi: 10.1007/s00467-022-05456-x. Epub 
      2022 Jan 27.